Merck KGaA (OTCMKTS:MKGAF) Shares Down 3.6% – Here’s Why

Merck KGaA (OTCMKTS:MKGAF)’s share price fell 3.6% during trading on Thursday . The stock traded as low as $151.46 and last traded at $151.46. Approximately 77 shares changed hands during mid-day trading, a decline of 87% from the average daily volume of 610 shares. The stock had previously closed at $157.0460.

Merck KGaA Price Performance

The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.84 and a current ratio of 1.31. The stock has a market capitalization of $19.61 billion, a PE ratio of 23.16 and a beta of 0.96. The company’s fifty day simple moving average is $161.40 and its two-hundred day simple moving average is $149.71.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Elefante Mark B acquired a new stake in Merck KGaA during the 2nd quarter valued at $617,000. Ames National Corp acquired a new stake in shares of Merck KGaA during the second quarter valued at $1,009,000. Notis McConarty Edward acquired a new stake in shares of Merck KGaA during the second quarter valued at $1,304,000. North Star Asset Management Inc. purchased a new stake in Merck KGaA during the 2nd quarter worth about $1,411,000. Finally, Pinnacle Holdings LLC purchased a new stake in Merck KGaA during the 2nd quarter worth about $1,487,000. 0.10% of the stock is currently owned by institutional investors and hedge funds.

Merck KGaA Company Profile

Merck KGaA is a Germany-based science and technology company headquartered in Darmstadt. Founded in 1668, it is one of the world’s oldest operating pharmaceutical and chemical companies. The business serves customers in more than 60 countries through three operating sectors: Healthcare, Life Science and Electronics.

The Healthcare sector develops and markets prescription medicines and specialty therapies, with activities focused on areas including oncology, neurology and immunology, fertility, and endocrinology.